Michael J. Kamdar is the president of Cellana, a developer of algae-based bioproducts. Previously, he was the chief business officer of Genoa Pharmaceuticals, a company developing a treatment idiopathic pulmonary fibrosis. Prior to Genoa, Mr. Kamdar founded VentiRx Pharmaceuticals, a privately held company focused on Toll-like Receptor 8 agonists (TLR8) for oncology, respiratory and inflammatory diseases, and served as a Board Member and Chief Business Officer from 2006 through 2011.
Over the past 20+ years, Mr. Kamdar has accounted for deal transactions in excess of $1.0B and raised in excess of $300M from venture capital and the public capital markets. Prior to VentiRx, Mr. Kamdar held several roles at Anadys Pharmaceuticals, most recently as SVP, Corporate Development and Finance including playing an instrumental role in the companies successful IPO. Prior to Anadys, Mr. Kamdar held several senior management positions at Agouron Pharmaceuticals, a Pfizer Company, most recently Vice President, Business Development. During his eight years at Agouron, Mr. Kamdar held various business development positions and responsibilities that culminated with his assumption of global responsibility for corporate partnering, in-licensing, technology acquisition, and strategic alliance efforts in the anti-infective, oncology, and ophthalmology therapeutic areas. Previously, Mr. Kamdar held various product management and new product planning positions for Hybritech, Inc., an Eli Lilly Company, and Centocor, Inc.
Mr. Kamdar is a member of the Board of Directors of Tobira Therapeutics, a privately held HIV company and BIOCOM, Southern California's life science industry organization. He received his B.S. in Biology from St. Joseph's University and his M.B.A. from Villanova University.